Known targets — ChEMBL curated mechanism
ABL1BMXBRAFBTKCHRNA4CHRNB2CSNK1EEGFRERBB2F10FLT1FLT3FLT4IGF1RINSRITKJAK3KDRKITOPRM1PARP1PARP2PDGFRBPIK3CDRAF1RETSLC18A2TECTXKdacAdacBdacCftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | SLC15A1 | P46059 | 1/20 | 0.45 |
| ▸ | TACR1 | P25103 | 3/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 2/20 | 0.44 |
| ▸ | CA2 | P00918 | 2/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | ALPI | P09923 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.44 |
| ▸ | XIAP | P98170 | 1/20 | 0.44 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | LTA4H | P09960 | 1/20 | 0.43 |
| ▸ | LAP3 | P28838 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2590490 | 1.00 | LMNA (0.52) | LMNAMAPTSLC15A1TACR1GAA | |
| SCHEMBL718199 | 1.00 | LMNA (0.52) | LMNAMAPTSLC15A1TACR1GAA | |
| SCHEMBL5115273 | 0.95 | MAPT (0.48) | LMNAMAPTSLC15A1TACR1GAA | |
| SCHEMBL12615481 | 0.95 | MAPT (0.48) | LMNAMAPTSLC15A1TACR1GAA | |
| SCHEMBL716533 | 0.95 | MAPT (0.48) | LMNAMAPTSLC15A1TACR1GAA | |
| SCHEMBL8813869 | 0.93 | P2RX7 (0.47) | LMNAMAPTSLC15A1TACR1GAA | |
| SCHEMBL6895557 | 0.93 | ALDH1A1 (0.50) | LMNAMAPTSLC15A1GAACA1 | |
| SCHEMBL8813866 | 0.93 | P2RX7 (0.47) | LMNAMAPTSLC15A1TACR1GAA | |
| SCHEMBL7302285 | 0.92 | LTA4H (0.56) | LMNAMAPTCA1CA2LTA4H | |
| SCHEMBL27403149 | 0.92 | MMP1 (0.46) | LMNAMAPTCA1CA2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4019528-B1 | BILE ACID DERIVATIVE, COMPOSITION AND APPLICATION THEREOF | SHENZHEN YUNHE PHARMACEUTICAL TECH PARTNERSHIP LIMITED (CN) | 2026-01-28 | — | — | EP | disclosed |
| US-12491190-B2 | Bile acid derivative, composition and application thereof | SHENZHEN YUNHE PHARMACEUTICAL TECHNOLOGY PARTNERSHIP (LIMITED) (CN) | 2025-12-09 | — | — | US | disclosed |
| CN-116925168-A | Bile acid derivatives, compositions and uses thereof | 深圳云合医药科技合伙企业(有限合伙) | 2023-10-24 | — | — | CN | disclosed |
| CN-112409435-B | Bile acid derivatives, compositions and uses thereof | 深圳云合医药科技合伙企业(有限合伙) | 2023-07-18 | — | — | CN | disclosed |
| US-20220273675-A1 | BILE ACID DERIVATIVE, COMPOSITION AND APPLICATION THEREOF | SHENZHEN YUNHE PHARMACEUTICAL TECHNOLOGY PARTNERSHIP (LIMITED) (CN) | 2022-09-01 | — | — | US | disclosed |
| EP-4019528-A1 | BILE ACID DERIVATIVE, COMPOSITION AND APPLICATION THEREOF | Shenzhen Yunhe Pharmaceutical Technology Partnership (Limited) (CN) | 2022-06-29 | — | — | EP | disclosed |
| WO-2021036998-A1 | BILE ACID DERIVATIVE, COMPOSITION AND APPLICATION THEREOF | 深圳云合医药科技合伙企业(有限合伙) | 2021-03-04 | — | — | WO | disclosed |
| CN-112409435-A | Bile acid derivatives, compositions and uses thereof | 深圳云合医药科技合伙企业(有限合伙) | 2021-02-26 | — | — | CN | disclosed |
| CN-101652365-A | 5,6,7,8-tetrahydropteridine derivatives as HSP90 inhibitors | ASTRAZENECA AB SE | 2010-02-17 | — | — | CN | disclosed |
| EP-0950656-B1 | SULFONATED AMINO ACID DERIVATIVES AND METALLOPROTEINASE INHIBITORS CONTAINING THE SAME | SHIONOGI & CO (JP) | 2007-04-11 | — | — | EP | disclosed |
| US-5597804-A | ANTITHROMBOTIC AGENTS | CORVAS INTERNATIONAL, INC. (US) | 1997-01-28 | — | — | US | disclosed |
| US-5595999-A | ANTICOAGULANTS | HOFFMANN-LA ROCHE INC. (US) | 1997-01-21 | — | — | US | disclosed |
| US-5583133-A | ANTICOAGULANTS | HOFFMANN-LA ROCHE INC. (US) | 1996-12-10 | — | — | US | disclosed |
| US-5532232-A | INHIBIT THROMBIN INDUCED PLATELET AGGREGATION; FIBRINOGEN ANTICOAGULANTS IN BLOOD | HOFFMANN-LA ROCHE INC. (US) | 1996-07-02 | — | — | US | disclosed |
| US-5393760-A | Cardiovascular disorders, antitumor agents | HOFFMANN-LA ROCHE INC. (US) | 1995-02-28 | — | — | US | disclosed |
| US-5371072-A | ANTICOAGULANTS | CORVAS INTERNATIONAL, INC. (US) | 1994-12-06 | — | — | US | disclosed |
| US-5260307-A | Inhibit thrombin-induced platlet aggregation and clotting of fibrogen in plasma | HOFMANN-LA ROCHE INC. (US) | 1993-11-09 | — | — | US | disclosed |
| US-5242903-A | Enzyme inhibitors | BAYER AKTIENGESELLSCHAFT (DE) | 1993-09-07 | — | — | US | disclosed |
| US-5095006-A | Enzyme inhibitors | BAYER AKTIENGESELLSCHAFT (DE) | 1992-03-10 | — | — | US | disclosed |
| EP-0412350-A2 | Renininhibitors, procedure for their preparation and use as medicaments | BAYER AG (DE) | 1991-02-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220273675-A1 | BILE ACID DERIVATIVE, COMPOSITION AND APPLICATION THEREOF | NR1H4, GPBAR1, GLP1R | LMNA 4572/4885MAPT 4033/4885SLC15A1 806/4885 |
| US-12491190-B2 | Bile acid derivative, composition and application thereof | NR1H4, GPBAR1, GLP1R | LMNA 4572/4885MAPT 4033/4885SLC15A1 806/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.